Previous 10 | Next 10 |
FHLC is a well-diversified healthcare ETF concentrated on large caps. FHLC generated strong return, and closely replicated returns of S&P 500. FHLC has strong price multiples and financial growth, at par with peers. For further details see: FHLC: Well Diversified, St...
To be a millionaire investor, you don't need to go looking at high-risk penny stocks to invest in. While that can be a quick way to turn a profit, it can also be a surefire way to lose all your money. Sometimes, all that's required to make a big profit is patience and investing in establish...
CWB invests in convertible securities. Historical performance. A tactical ETF rotation. For further details see: CWB: Portfolio And Performance Update
Dexcom CGM use is proven to improve glycemic control 1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring. 3 Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CG...
IHI is one of the rare healthcare ETF to outperform S&P 500. IHI’s significant holdings has generated considerable price growth. Healthcare equipment and Medical Devices sector has stood out during the pandemic crisis, and is expected to grow further. For further ...
ResMed is a great company operationally, with an attractive growth record for sales, profits, and cash flows. Long term, the company will likely continue to do well, with recent growth coming in strong. But shares ultimately look incredibly overpriced even if they are fairly value...
DexCom (NASDAQ:DXCM) said the U.S. FDA granted Breakthrough Device Designation for Dexcom CGM use in the hospital setting. Dexcom CGM uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device, providing real-time glucose data wi...
Dexcom CGM to be evaluated for performance in the hospital and for the potential of more effective glycemic management and improved patient outcomes in the hospital setting Breakthrough Device Designation from the FDA is a critical milestone for in-patient Dexcom CGM use ...
While the average U.S. worker can count on receiving monthly Social Security benefits in retirement, these payments aren't meant to replace a person's entire paycheck. That's why it's crucial to build a nest egg independent of government programs to support people who are aging. One gre...
Even with significant success over the past four years, DexCom (NASDAQ: DXCM) appears set to continue its growth in 2022 and beyond. In this segment of "The Earnings Show" on Motley Fool Live , recorded on Feb. 11 , Fool contributors Taylor Carmichael and Brian Withers discu...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 10:00:00 ET Growth-oriented investors have experienced a bit of a roller-coaster ride over the past few years. Many companies in the "growth stock" category were struggling just two years ago, but in the bull market we are now experiencing, they're delivering very different resul...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...